Abstract |
Tigecycline belong to glycylcycline antibiotics. This new group of antibiotics was derived from lipophilic tetracyclines but differs from them by higher effectivity, lower affinity to bacterial resistance mechanisms, and very long half-time. Tigecycline is registered for treatment two groups of infections: skin and soft tissue infections and complicated intra-abdominal infections. Nevertheless, its therapeutic use probably can be enlarged to pneumonia, STD, infections caused by multi-resistant Helicobacter pylori, subacute and chronic infections associated with biofilm formation, and serious infections caused by intracellular pathogens (serious brucellosis, Q-fever, rickettsial infections). By contrast, tigecycline seems not appropriate for treatment sepsis and similar acute life-threatening bacterial diseases.
|
Authors | Jirí Benes, Olga Dzupová |
Journal | Klinicka mikrobiologie a infekcni lekarstvi
(Klin Mikrobiol Infekc Lek)
Vol. 15
Issue 1
Pg. 7-13
(Feb 2009)
ISSN: 1211-264X [Print] Czech Republic |
Vernacular Title | Tigecyklin: Zarazení mezi ostatními antibiotiky, vlastnosti, klinické vyuzití. |
PMID | 19399724
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Tigecycline
- Minocycline
|
Topics |
- Anti-Bacterial Agents
(chemistry, therapeutic use)
- Bacteria
(growth & development)
- Humans
- Minocycline
(analogs & derivatives, chemistry, therapeutic use)
- Tigecycline
|